Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study

#1437

Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.

Aim(s): To evaluate efficacy and safety of EVE in pts with lung NET from RADIANT-4.

Materials and methods: In RADIANT-4 study, pts were randomized (2:1) to EVE 10 mg/d or PBO, both with best supportive care. The present analysis reports subgroup of lung NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Fazio N

Authors: Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E,

Keywords: PFS, Everolimus, Lung carcinoid,

To read the full abstract, please log into your ENETS Member account.